Download
00432_2024_Article_6014.pdf 1017,86KB
WeightNameValue
1000 Titel
  • Preferences of melanoma patients to accept adjuvant therapy and toxicity – a qualitative substudy of the GerMelaTox-A project
1000 Autor/in
  1. Janke, Toni Maria |
  2. Moysig, Laura |
  3. Blome, Christine |
  4. Kähler, Katharina |
1000 Verlag Springer Berlin Heidelberg
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-12-04
1000 Erschienen in
1000 Quellenangabe
  • 151(1):3
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00432-024-06014-8 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11614979/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose</jats:title> <jats:p>Targeted treatment and immunotherapy, both adjuvant treatment options, come with a certain toxicity and can cause severe side effects. To date, data about the underlying reasons for patients to accept or reject specific types of adjuvant therapy is scarce. Therefore, this study investigates the motives of melanoma patients for tolerating or rejecting adjuvant therapy and its side effects.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>We conducted semi-structured interviews with a subsample of patients to investigate the underlying reasons for treatment decisions in a quantitative treatment-trade off study. Categorisation was conducted using qualitative content analysis.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>The 17 participants had a mean age of 55.5 years and 12 were female. The final category system covered three clusters. The cluster “type of therapy and therapy process” described therapy-related aspects that affect acceptability of adjuvant treatments. Prospect of treatment benefit and side effects were important aspects. Route of administration and physician visits should be convenient. The cluster “way of living” described the influence that activities and circumstances of life organisation have on acceptability. Participants wished treatment to affect everyday life as little as possible. Maintaining sufficient quality of life was mentioned to be crucial. The cluster “emotions and feelings” described optimism and hope but also mental strain originating from possible treatment options.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Patients in our study indicate high willingness to undergo adjuvant therapy, even when facing toxicity. The evaluation of potential side effects and prospects of treatment benefit is highly individual. Therefore, it is important to consider personal patient preferences to make appropriate and shared decision-making.</jats:p> </jats:sec>
1000 Sacherschließung
lokal Melanoma/therapy [MeSH]
lokal Female [MeSH]
lokal Skin Neoplasms/psychology [MeSH]
lokal Melanoma
lokal Qualitative interviews
lokal Aged [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Patient Acceptance of Health Care/psychology [MeSH]
lokal Middle Aged [MeSH]
lokal Skin Neoplasms/drug therapy [MeSH]
lokal Melanoma/psychology [MeSH]
lokal Immunotherapy/adverse effects [MeSH]
lokal Adjuvant therapy
lokal Immunotherapy/methods [MeSH]
lokal Qualitative Research [MeSH]
lokal Male [MeSH]
lokal Quality of Life [MeSH]
lokal Research
lokal Chemotherapy, Adjuvant/adverse effects [MeSH]
lokal Patient preferences
lokal Patient Preference/psychology [MeSH]
lokal Melanoma/drug therapy [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-9861-9519|https://frl.publisso.de/adhoc/uri/TW95c2lnLCBMYXVyYQ==|https://orcid.org/0000-0002-1163-1639|https://orcid.org/0000-0001-9953-0893
1000 Hinweis
  • DeepGreen-ID: 21a0da00d4f0494d8500516a72336783 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Universitätsklinikum Hamburg-Eppendorf (UKE) |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Universitätsklinikum Hamburg-Eppendorf (UKE) |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6504255.rdf
1000 Erstellt am 2025-02-06T01:01:13.845+0100
1000 Erstellt von 322
1000 beschreibt frl:6504255
1000 Zuletzt bearbeitet 2025-09-13T14:30:48.982+0200
1000 Objekt bearb. Sat Sep 13 14:30:48 CEST 2025
1000 Vgl. frl:6504255
1000 Oai Id
  1. oai:frl.publisso.de:frl:6504255 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source